Accueil>>Alpha-Lipoic Acid Choline Ester

Alpha-Lipoic Acid Choline Ester (Synonyms: EV-06; EV06; EV 06; alpha-LACE; alphaLACE; alpha LACE; UNR844; UNR-844; UNR 844; Alpha-Lipoic Acid Choline Ester;)

Catalog No.GB62240

Alpha-Lipoic Acid Choline Ester, also known as alpha-LACE, EV-06 or UNR844, is a drug candidate potentially for the treatment of presbyopia.

Products are for research use only. Not for human use. We do not sell to patients.

Alpha-Lipoic Acid Choline Ester Chemical Structure

Cas No.: 1808266-58-1

Taille Prix Stock Qté
50mg
150,00 $US
En stock
100mg
250,00 $US
En stock
200mg
450,00 $US
En stock
500mg
950,00 $US
En stock
1g
1 650,00 $US
En stock
2g
2 950,00 $US
En stock
5g
6 650,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Alpha-Lipoic Acid Choline Ester, also known as alpha-LACE, EV-06 or UNR844, is a drug candidate potentially for the treatment of presbyopia. Alpha-LACE was designed to permeate biological membranes with the incorporation of the cationic choline head group. While lipoic acid does not permeate the cornea, the choline ester derivative of lipoic acid permeates the cornea, is hydrolyzed by corneal esterases and is transformed into the biologically active lipoic acid. LACE has been formulated into an ophthalmic solution to be applied twice daily as an eye-drop to treat presbyopia.

Avis

Review for Alpha-Lipoic Acid Choline Ester

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Alpha-Lipoic Acid Choline Ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.